Among the Eli Lilly trials is one for orforglipron (LY3502970), a novel, oral non-peptide GLP-1 RA, which is the subject of four trials in the clinicaltrials.gov data
The therapeutic reach of GLP-1 RAs is currently undergoing an "Indication Land Grab." As clinical data accumulates, these molecules are being explored across multiple organ systems, driven by their ability to modulate inflammation, mitochondrial efficiency, and metabolic signaling
In addition, we provide a comprehensive review of recent advancements in utilizing MSC-Exos as a therapeutic strategy to modulate ferroptosis in different disease models
doi: 10.1080/19490976.2020.1824563 46 ChouayekhH.Farhat-KhemakhemA.KarrayF.BoubakerI.MhiriN.AbdallahM.et al
This result indicates that the addition of L-carnitine to sertraline did not exacerbate treatment complications
A slow stroll around the block works